Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis-Reference-Cited by-同舟云学术

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Published:2018-12 Issue:12 Volume:16 Page:1983-1991.e3
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Lawitz Eric J.,Coste Angie,Poordad Fred,Alkhouri Naim,Loo Nicole,McColgan Bryan J.,Tarrant Jacqueline M.,Nguyen Tuan,Han Ling,Chung Chuhan,Ray Adrian S.^ORCID,McHutchison John G.,Subramanian G. Mani,Myers Robert P.,Middleton Michael S.^ORCID,Sirlin Claude,Loomba Rohit,Nyangau Edna,Fitch Mark^ORCID,Li Kelvin^ORCID,Hellerstein Marc

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference29 articles.

1. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease;Angulo;Gastroenterology,2015

2. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites;Neuschwander-Tetri;Hepatology,2010

3. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study;Stiede;Hepatology,2017

4. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis;Loomba;J Lipid Res,2015

5. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease;Hall;Hepatology,2017

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Acetyl-CoA carboxylase Inhibition increases retinal pigment epithelial cell fatty acid flux and restricts apolipoprotein efflux;Journal of Biological Chemistry;2024-09

3. Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges;Frontiers in Pharmacology;2024-08-06

4. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?;Metabolism;2024-08

5. Hepatic glucagon action: beyond glucose mobilization;Physiological Reviews;2024-07-01